Cabergolin therapy of hyperprolactinemia associated with intake of neuroleptics

Hyperprolactinemia associated with intake of neuroleptics (HAN) is a commonest endocrine disorder encountered in psychiatric practice. Approaches to the treatment of this condition remain to be developed. It is supposed that the use of dopamine receptor agonists may cause deterioration of the patients' psychic status. We have studied the influence of therapy with cabergolin on 44 patients presenting with HAN. It was shown that the long-term treatment using cabergolin is a safe and efficacious therapeutic modality for the patients suffering from psychic disorders. The frequency of exacerbation of psychic disorders in the group of patients treated with cabergolin was lower than in the control group. It is concluded that the correction of HAN by cabergolin in the patients presenting with psychic disorders leads to the significant improvement of reproductive and sexual functions.

hyperprolactinemia, prolactin, neuroleptics, cabergolin, schizophrenia, psychic disorder

1. Горобец Л.Н., Буланов В.С. Сравнительная эффективность и переносимость коррекционной терапии каберголином (Достинексом) и бромокриптином синдрома нейролептической гиперпролактинемии у больных с психическими расстройствами. // Психиатрия и психофармакотерапия. 2011;(1):22-27. [Gorobets LN, Bulanov VS. Comparative efficacy of Dostinex vs Bromocriptine in therapy of hyperlactinemia in psychiatric patients. Psikhiatriya i psikhofarmakoterapiya. 2011;(1):22-27.]

2. Мельниченко Г.А., Гончаров Н.П., Дзеранова Л.К., и др. Клинические и лабораторные аспекты исследования изоформ пролактина методом ПЭГ-преципитации и ультрафильтрации. // Проблемы эндокринологии. 2010;56(1):19-25. [Mel'nichenko GA, Goncharov NP, Dzeranova LK, Dobracheva AD, Barmina II. Clinical and laboratory aspects of investigations into prolactin isoforms by PEG precipitation and ultrafiltration techniques. Problemy Endokrinologii. 2010;56(1):19-25.] doi: 10.14341/probl201056119-25

3. Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C. Hyperprolactinémies induites par les antipsychotiques : physiopathologie, clinique et surveillance. L'Encéphale. 2014;40(1):86-94. doi: 10.1016/j.encep.2012.03.002

4. Chang S-C, Chen C-H, Lu M-L. Cabergoline-induced psychotic exacerbation in schizophrenic patients. General Hospital Psychiatry. 2008;30(4):378-380. doi: 10.1016/j.genhosppsych.2007.11.002

5. Lee M-S, Song H-C, An H, Yang J, Ko Y-H, Jung I-K, et al. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: Eight-week randomized, single-blind, placebo-controlled, multicenter study. Psychiatry and Clinical Neurosciences. 2010;64(1):19-27. doi: 10.1111/j.1440-1819.2009.02032.x

6. Barszcz Z, Mucha S, Rabe-Jablonska J. The assessment of the mental state of patients during simultaneous treatment with psychotropic drugs, antipsychotics included, and bromocriptine. Psychiatria Polska. 2008;42(4):595-607. PMID:19189603

7. Pollice R, Di Giovambattista E, Tomassini A, Di Pucchio A, Mazza M, Di Michele V, et al. Risperidone-induced symptomatic hyperprolactinemia in youth with schizophrenia: efficacy and tolerability of cabergoline treatment. La Clinica Terapeutica. 2007;158(2):121-126. PMID:17566512

8. Kalkavoura CS, Michopoulos I, Arvanitakis P, Theodoropoulou P, Dimopoulou K, Tzebelikos E, et al. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. Experimental and Clinical Psychopharmacology. 2013;21(4):332-341. doi: 10.1037/a0033448

9. Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. The Journal of Clinical Psychiatry. 2004;65(2):187-90. PMID:15003071

10. Ware JE, Gandek B. Overview of the SF-36 Health Survey and International Quality of Life Assessment (IQOLA) Project. Journal of Clinical Epidemiology. 1998;51(11):903-912. PMID: 9817107

11. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica. 1987;76(s334):1-100. doi: 10.1111/j.1600-0447.1987.tb10566.x

12. Montejo ÁL, Rico-Villademoros F. Psychometric Properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in Patients with Schizophrenia and Other Psychotic Disorders. Journal of Sex and Marital Therapy. 2008;34(3):227-239. doi: 10.1080/00926230701866125